The benefit of EXtending oral blood thinning(antiCOAgulant) treatment after acute blockage of cerebral veins(cerebral venous thrombosis-CVT) (EX-COA CVT)

Not Applicable

• Conditions: Health Condition 1: null- patients with cerebral venous sinus thrombosis,within month of event

• Registration Number: CTRI/2017/08/009564
• Lead Sponsor: niversity of Lisbon

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Patients with acute symptomatic and radiologically confirmed CVT ï? 

2.Age 18 years OR above at entry ï? 

3.CVT must have been diagnosed in less than 1 month before inclusion ï? 

4.The patient must be clinically stable and able to stop parenteral anticoagulation in order to initiate oral anticoagulation ï?  ï?¡

5.Written informed consent

Exclusion Criteria

1.Systemic life-threatening or major bleeding while on anticoagulants during the acute phase of CVT or during the 6 months prior to randomisation (intracranial bleeding due to inclusion CVT is not an exclusion criteria) ï?  ï?¡

2.General contraindications for anticoagulant therapy ï? 

3.Need for prolonged treatment with antiplatelet drugs, non-steroidal anti-inflammatory drugs or other drugs/diseases that interferes significantly with anticoagulant therapy or with INR ï?  ï?¡

4.Life expectancy less than 2 years due to a pre-existing condition (including any malignancy) ï? 

5.Child bearing potential without adequate contraceptive measures, pregnancy or breast feeding ï? 

6.Known allergy to study medications ï? 

7.Other conditions judged by the investigator to be an absolute indication for prolonged oral anticoagulation

such as recurrent CVT, VTE after CVT or first CVT with antiphospholipid syndrome or known severe

thrombophilia (antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation or combined abnormalities)

Study & Design

• Study Type: Observational
• Study Design: Not specified